Replies to post #14907 on Guided Therapeutics Inc (GTHP)

[Franken-vestor]

I bet you're really cute in your a little romper with your pig tails!

[GetSeriousOK]

I can answer those.

Is this incompetent CEO “ever” going to publish S-1?

This CEO is not incompetent. Far from it. He brought GuidedThera up from the ashes by clearing out the toxic debt and UPLISTING and getting the FDA trial started again. Amazing, IMO. Never seen anything like this in the pinksheets before.

Nobody here knows whether the company (not the CEO mind you, the COMPANY) will file that S-1. My educated guess is yes, they will, because they need to do that to pay for the clinical trial, and the accomplishments in the past year point towards this company being serious about getting FDA clearance/approval.

What’s status of SMI’s clinical trials? Weren’t they supposed to start clinical trials in summer? What’s status of SMI’s application for CFDA approval?

Forget about SMI. They have accomplished nothing and they WILL accomplish nothing. Who knows whether GuidedThera knew this all along or whether they actually believed SMI's BS in 2017-2019 but if you read my posts I have been saying for the past three years that SMI is China Hype and SMI will never get CFDA approval.

If you read the last couple of financial filings, you will learn that SMI has done nothing. After three years of SMI promises, they have done nothing.

CFDA approval is just as difficult if not MORE difficult to get that FDA approval. More important: SMI seems to be saying that the CFDA will classify the LuViva Scan as a Class II device, and that is nonsense, IMO. The US FDA is classifying it as Class III so of course the CFDA will too.

So in summary:

* Yes this company will file that S-1.
* SMI has done nothing, is doing nothing, and will do nothing.

[GetSeriousOK]

There's the S-1. This answers all three of your questions but we all know that won't matter.

The filing of the S-1 isn't going to budge the PPS because nobody reads SEC filings. However, it is a momentous event. It proves that Gene is serious about keeping this boat above water, and it means Guided will now get funding to complete the clinical trials.

I skimmed the S-1 but it doesn't tell us anything we didn't already know. 40 million new shares are being registered. Some of these shares were already issued in December, and many will only be issued upon conversion of the Series D Preferred and/or Series E Preferred, which realistically won't happen for awhile, especially the shares priced at 75 cents.

Regarding SMI: officially, SMI has until the end of January 2021 to get CFDA approval or they turn to dust (18 months from July 24, 2019). I gave up on SMI last summer, but we can all officially give up on SMI in five months. Buh bye, SMI.